ARMP - Armata Pharmaceuticals, Inc.

NYSE American - NYSE American Delayed Price. Currency in USD
3.6000
+0.2050 (+6.04%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close3.3950
Open3.4300
Bid3.4600 x 1000
Ask3.6000 x 800
Day's Range3.4000 - 3.6000
52 Week Range2.1000 - 19.1800
Volume13,383
Avg. Volume108,144
Market Cap35.856M
Beta (3Y Monthly)3.17
PE Ratio (TTM)N/A
EPS (TTM)-0.1800
Earnings DateAug 7, 2019 - Aug 12, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est8.00
Trade prices are not sourced from all markets
  • Armata Pharmaceuticals to Host Key Opinion Leader Meeting on Bacteriophage-Based Therapeutics on June 26 in New York
    PR Newswirelast month

    Armata Pharmaceuticals to Host Key Opinion Leader Meeting on Bacteriophage-Based Therapeutics on June 26 in New York

    MARINA DEL REY, Calif., June 18, 2019 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP), a clinical-stage biotechnology company focused on precisely targeted bacteriophage therapeutics for antibiotic-resistant infections, today announced that it will host a Key Opinion Leader (KOL) meeting on phage-based therapeutics for the treatment of antimicrobial-resistant infections on June 26 from 12:00 – 1:30 PM EDT in New York City. The event will feature a presentation by Robert Schooley, MD, from the University of California-San Diego, who will discuss the rapidly growing antibiotic resistance crisis and the urgent need for the development of new antibiotic alternatives. Armata's management team will also provide an overview of the company's phage-based product candidates aimed to address areas of significant unmet clinical need by targeting key antibiotic-resistant bacteria.

  • Armata Pharmaceuticals Strengthens Intellectual Property Portfolio with New Patent Allowances in Europe and Canada
    PR Newswire2 months ago

    Armata Pharmaceuticals Strengthens Intellectual Property Portfolio with New Patent Allowances in Europe and Canada

    MARINA DEL REY, Calif., June 3, 2019 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP), a clinical-stage biotechnology company focused on precisely targeted bacteriophage therapeutics for antibiotic-resistant infections, today announced that the company continues to strengthen its intellectual property portfolio with the allowance of two patents by the European Patent Office and one allowance by the Canadian Intellectual Property Office.

  • Armata Pharmaceuticals Announces Publication of Successful Adjunctive Phage Treatment in Cystic Fibrosis Patient
    PR Newswire2 months ago

    Armata Pharmaceuticals Announces Publication of Successful Adjunctive Phage Treatment in Cystic Fibrosis Patient

    MARINA DEL REY, Calif, May 28, 2019 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP), a clinical-stage biotechnology company focused on precisely targeted bacteriophage therapeutics for antibiotic-resistant infections, today announced the publication of a case study involving a cystic fibrosis patient who was successfully treated for a multidrug-resistant Pseudomonas aeruginosa infection with the Company's natural phage product, AP-PA01. The paper, entitled "Successful adjunctive use of bacteriophage therapy for treatment of multidrug‑resistant Pseudomonas aeruginosa infection in a cystic fibrosis patient," appears in the peer-reviewed journal Infection.